London – October 5, 2021 – Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.
Goldman Sachs, Morgan Stanley, BofA Securities and Barclays Capital acted as joint book-running managers for the offering. The American depositary shares began trading on the Nasdaq Global Select Market under the symbol "EXAI" on October 1, 2021.
Exscientia is committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. The company developed the first functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as move AI-designed small molecules into the clinical setting. Exscientia's pipeline demonstrates its ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.